Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
”ASCO26 update in atypical EGFR+ NSCLC from CHRYSALIS-2, presented by Joel W. Neal.
1L amivantamab + lazertinib (n=49)
- mOS: 41 mos
- 55% alive at 3 yrs
- 46% alive at 4 yrs
20% remain on tx
7 pts stayed on amivantamab >3 years
For context, historical afatinib mOS: ~19 mos.”
Other Articles Featuring Eric Singhi On OncoDaily.
